Guidance regarding gamete and embryo donation

Practice Committee of the American Society for Reproductive Medicine and the Practice Committee for the Society for Assisted Reproductive Technology

American Society for Reproductive Medicine and Society for Assisted Reproductive Technology, Birmingham, Alabama

This document provides the latest recommendations for the evaluation of potential sperm, oocyte, and embryo donors as well as their recipients, incorporating recent information about optimal screening and testing for sexually transmitted infections, genetic diseases, and psychological assessments. This revised document incorporates recent information from the US Centers for Disease Control and Prevention, US Food and Drug Administration, and American Association of Tissue Banks, which all programs offering gamete and embryo donation services must be thoroughly familiar with, and replaces the document titled "Recommendations for gamete and embryo donation: a committee opinion," last published in 2013. (Fertil Steril® 2021;115:1395–410. ©2021 by American Society for Reproductive Medicine.)

El resumen está disponible en Español al final del artículo.

**Key Words:** Sperm, oocyte, donor insemination, donor screening, quarantine

**Discuss:** You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/posts/32311

**TABLE OF CONTENTS**

I. Introduction

II. Donors indications, screening, and selection

a. Sperm Donation

i. Indications for donor sperm insemination

ii. Donor sperm screening

iii. Donor sperm selection

iv. Directed (nonanonymous/known) donation

v. Quarantine of semen

vi. Use of fresh semen

b. Oocyte Donation

i. Indications for use of donor oocytes

ii. Oocyte donor screening

iii. Oocyte donor selection

iv. Directed (nonanonymous/known) oocyte donation

v. Quarantine of oocytes

vi. Requirements of clinics providing oocyte donation services

c. Embryo Donation

i. Guidance for ART practices that offer embryo donation

ii. Donor embryo screening

iii. Donor embryo eligibility

iv. Situations in which the gamete source was a donor, not an intimate partner

III. Management of sperm/oocyte donors

IV. Recipients and their partners—screening and testing

a. ASRM-recommended evaluation of recipients

b. ASRM-recommended recipient partner screening

V. Psychoeducational counseling—donors and recipients

a. ASRM-Recommended Psychoeducational Counseling—Donors

b. Psychoeducational Consultation: Gamete Donation Recipients (Oocytes, Sperm, and Embryos)

c. Psychoeducational Consultation: Gamete (Sperm and Oocyte) Donation with a Directed Donor

d. Psychoeducational Consultation: Embryo Donation with a Directed Donor

VI. Genetic screening and counseling—donors and recipients

a. Genetic Carrier Screening for Heritable Diseases

i. Recommended non-identified (anonymous) donor carrier screening

ii. Donor counseling

iii. Donor eligibility

iv. Recipient counseling

b. Family History Screening for Non-Identified (Anonymous) Donors

i. Recommended donor family history screening

ii. Donor counseling

iii. Non-identified (anonymous) donor eligibility

1. Monogenic conditions

2. Congenital anomalies

3. Multifactorial conditions

4. Chromosomal conditions

iv. Recipient counseling

VII. Legal considerations—donor and recipients

VIII. FDA donor eligibility—questionnaire, physical exam, laboratory testing
a. FDA Donor Eligibility Medical Questionnaire
b. FDA Donor Eligibility Laboratory Testing
   i. Managing laboratory results
c. FDA Donor Eligibility Physical Exam

IX. References

I. INTRODUCTION

The use of sperm, oocyte, and embryo donation services has increased over the past several decades [1–3]. The availability of donor gametes provides individuals and couples who otherwise may not be able to conceive with an opportunity to build a family. To optimize safety and outcomes, the US Food and Drug Administration (FDA), American Association of Tissue Banks, US Centers for Disease Control and Prevention (CDC), and American Society for Reproductive Medicine (ASRM) have developed their own guidance for the screening of donor tissue and recipients.

This document aims to summarize the current guidance for donor eligibility determination that has been mandated by FDA before the use of donor oocytes, sperm, or embryos. Donors are defined as individuals who are not sexually intimate partners of the recipients; donor eligibility determination is required for donor sperm, donor oocytes, donor embryos, and sperm and oocyte sources when planning to use a gestational carrier. This guidance also reviews the screening of donors and recipients that has been recommended by CDC and ASRM. Although FDA donor eligibility determination focuses on infectious risk, the ASRM guidance also incorporates prenatal optimization, psychoeducational counseling of donors and recipients, and genetic risk assessment.

This guidance for the screening and testing of gamete and embryo donors applies to all potential donors in the United States. Because the prevalence of sexually transmitted infections (STIs) may vary in other locales, this guidance may not be appropriate for other countries or individuals who come to the United States from other countries. If a donor is deemed “ineligible” based on the FDA guidance detailed herein, the tissue cannot be used for a non-identified (anonymous) donation. However, for a directed or known donation, the “ineligible” tissue may be used if both parties are aware of the theoretical infectious or genetic risk and consent to move forward with the donation.

Throughout this document, “anonymous” donors have been referred to as “non-identified.” The transition in language from “anonymous” to “non-identified” reflects the realization that anonymity is decreasing with the prevalence of and access to nonmedical genetic testing.

Oocyte donation, and thereby this document, does not apply to lesbian couples who undergo reciprocal in vitro fertilization (IVF), in which one partner provides the oocyte(s) and the other partner carries the pregnancy. In this setting, the partner does not donate her oocytes. The oocytes should be considered shared between sexually intimate partners because sperm is shared between heterosexual couples, presumed to be sexually intimate.

Although FDA does not require screening or testing of the recipients of donated gametes, ASRM recommends the evaluation of recipients as described. Other areas where the ASRM recommendations may be more stringent than the FDA minimum requirements are noted herein. Additionally, state requirements may be more restrictive than those of FDA, and clinics are encouraged to check with government officials in the state where their practice is located to determine minimum screening and testing requirements for their state.

The promulgation of FDA regulations has caused considerable oversight of gamete and embryo donation, including mandatory registration of all assisted reproductive technology (ART) programs with the federal government, federal inspections of programs that perform donation, required documentation, and written protocols related to donor screening, testing, selection, rejection, and follow-up. Complete records of all donor cycles, including the documentation of adherence to FDA regulations, must be made available to FDA inspectors at their request. Federal regulations and frequently asked questions and answers may be viewed at the following websites:


II. DONORS—INDICATIONS, SCREENING, AND SELECTION

a. Sperm Donation

Donated sperm for use for donor insemination (DI) or IVF may be performed with directed (known) or non-identified (anonymous) donors depending on clinical circumstances. Donor sperm use has increased over the past 20 years [3].

i. Indications for donor sperm insemination. Indications for donor sperm insemination may include but not limited to the following:

- The male partner has azoospermia, severe oligozoospermia, or other significant sperm or seminal fluid abnormalities.
- The male partner has ejaculatory dysfunction.
- Prior failure to fertilize during IVF after insemination with intracytoplasmic sperm injection.
- The male partner has a significant genetic defect or the couple has previously produced an offspring affected by a condition for which carrier status cannot be determined or the couple has a strong family history of a heritable disease.
- The female partner is Rh-negative and severely Rh-immunized and the male partner is Rh-positive.
- A female without a male partner or with a transmale partner.

ii. Donor sperm screening. There is no method to completely ensure that infectious agents will not be transmitted by DI. However, the following guidance [Table 1 (4–6)], combined
with adequate information about the donor’s history and specific exclusion of individuals at a high risk of human immunodeficiency virus (HIV) and other STIs, should significantly reduce these risks.

- Medical history—See “Donor Eligibility Medical Questionnaire” list [4, 5].
- Physical examination—See “FDA Donor Eligibility Physical Exam” [6].
- Laboratory testing—See “FDA Donor Eligibility Laboratory Testing” within 7 days of semen production [4].

iii. Donor sperm selection.
- The main qualities to seek while selecting a donor for DI are assurance of good health and normal semen analysis results. There are no uniformly accepted standards, but, in general, the minimum criteria for normal semen quality can be applied [9].
  - Genetic evaluation: The donor should undergo appropriate genetic evaluation, as reviewed in the genetic counseling section herein (see “Genetic Screening and Counseling”).
- The donor should be of legal adult age in their state, ideally ≥ 21 years, and should ideally be young enough so that the risks to the offspring associated with an increased paternal age, such as autism, are minimized. Donors <21 years of age should undergo psychological evaluation by a qualified mental health professional, and the decision to proceed with a donor <21 years of age should be made on an individual basis with help from a qualified mental health professional.

- Psychological evaluation and counseling by a qualified mental health professional is strongly recommended for all sperm donors (see “Psychoeducational Counseling—Donors and Recipients”).
- Donors should be healthy and give no history to suggest hereditary disease. Proven fertility in the donor is desirable but not required.
- No owner, operator, laboratory director, trainee, or employee of a facility providing donor sperm or performing DI may serve as a donor in that practice.

iv. Directed (nonanonymous/known) donation. Directed (nonanonymous or known) donation is acceptable if all parties agree. Directed donors must undergo the same infectious disease screening and testing as non-identified donors. Directed donors who test positive or demonstrate a risk of hereditary disease are deemed “ineligible” for non-identified (anonymous) donation. However, they are not prohibited from being used in directed donation according to current FDA rules, provided that both parties are aware of the donation’s theoretical infectious or genetic risk and have provided their consent to move forward with the donation. Although FDA does not inform the recipients of the test results other than their eligibility status, in the opinion of ASRM, the recipients must be informed and appropriately counseled with the donor’s consent before using the samples.

v. Quarantine of semen. While 6-month quarantine is required by the FDA for non-identified (anonymous) semen donation, directed donor specimens are exempted from quarantine under the current FDA guidance, which only requires testing within 7 days of donation. However, in the opinion...
of ASRM, quarantine of directed donor specimens for 35 days, followed by retesting for infectious diseases, is recommended. Current evidence suggests that the chance of having undetected HIV or hepatitis B 35 days after an initial negative quantitative test result is extremely low; the risk of undetected infection was <1/1 × 10⁶ for HIV after 14 days, for hepatitis B after 35 days, and for hepatitis C after 7 days from the time of potential exposure until the day of a negative nucleic acid amplification test (10).

v. Use of fresh semen. In the opinion of ASRM, the use of fresh semen can be justified only for sexually intimate partners. It is possible for HIV and other infectious organisms to be transmitted via fresh donor semen before the donor becomes seropositive. Consequently, the potential for transmission of infections by fresh semen cannot be eliminated.

b. Oocyte Donation

Oocyte donation may be undertaken with directed (known) or non-identified (anonymous) donors. Oocyte donation requires that the donor undergo ovarian stimulation with monitoring and oocyte retrieval, involving significant inconvenience, discomfort, and risks for the donor. Women may choose to donate oocytes more than once, increasing the potential risk to the health of the donor [see the ASRM Practice Committee document titled “Repetitive oocyte donation: a committee opinion” for further information on this topic (11)]. Women donating oocytes for reproductive purposes should be compensated based on ethical grounds [see ASRM Ethics Committee document titled “Financial compensation of oocyte donors: an ethics committee opinion” for further discussion (12)].

i. Indications for use of donor oocytes. Indications may include but not limited to the following:

- Women with hypergonadotrophic hypogonadism
- Women of advanced reproductive age
- Women who have diminished ovarian reserve
- Women who are known to be affected by or known to be the carrier of a significant genetic defect or who have a family history of a condition for which carrier status cannot be determined
- Women with poor oocyte and/or embryo quality or multiple previous failed attempts to conceive via ART
- Men who do not have a female partner or those who have a transfemale partner and are planning to use a gestational carrier

ii. Oocyte donor screening. There is no method to completely ensure that infectious agents are not be transmitted via donor oocytes. However, the following guidance [Table 2 (4, 5)], combined with adequate information about the donor’s history and specific exclusion of individuals at a high risk of HIV and other STIs, should significantly reduce these risks.

- Medical history—See “FDA Donor Eligibility Medical Questionnaire” list (4, 5).
- Physical examination—See “FDA Donor Eligibility Physical Exam” (6).
- Laboratory testing—See “FDA Donor Eligibility Laboratory Testing” within 30 days of drug at or up to 7 days after acquisition (4).

iii. Oocyte donor selection.

- Oocyte donors should be of legal age in their state and preferably between the ages of 21 and 34 years. Donors <21 years of age should undergo psychological evaluation by a qualified mental health professional, and the decision to proceed with such a donor should be determined on an individual basis. If a prospective donor is >34 years of age, the age of the donor should be revealed to the recipient as part of the informed consent discussion to address genetic risks and the effect of donor age on pregnancy rates.
- Donors should be healthy and give no history to suggest hereditary disease. Proven fertility in the donor is desirable but not required. Pelvic ultrasound for the assessment of pelvic anatomy, including the ovaries, is recommended for antral follicle count. Additional measurement of serum biomarkers of the ovarian reserve is warranted to anticipate the response to oocyte stimulation.

### TABLE 2

<table>
<thead>
<tr>
<th>Donor oocyte FDA requirements and ASRM recommendations (4, 5).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FDA requirement</strong></td>
</tr>
<tr>
<td>✔ Donor physical examination(^a)</td>
</tr>
<tr>
<td>✔ Donor questionnaire(^b,c)</td>
</tr>
<tr>
<td>✔ Donor infectious laboratory tests at an FDA-approved laboratory 30 days before, or up to 7 days after(^d) oocyte acquisition</td>
</tr>
<tr>
<td>✔ Non-identified (anonymous); must be ELIGIBLE to use tissue</td>
</tr>
<tr>
<td>✔ Directed (known); ineligible tissue may be used but with appropriate labeling and consent</td>
</tr>
<tr>
<td><strong>ASRM recommendation (in addition to FDA requirements)</strong></td>
</tr>
<tr>
<td>✔ Psychoeducational counseling</td>
</tr>
<tr>
<td>✔ Genetic screening</td>
</tr>
<tr>
<td>✔ Medical history</td>
</tr>
<tr>
<td>✔ Infectious disease testing of recipient and recipient’s sexually intimate partners</td>
</tr>
<tr>
<td>✔ Legal consultation, particularly for directed donation</td>
</tr>
</tbody>
</table>

Note: ASRM = American Society for Reproductive Medicine; FDA = U.S. Food and Drug Administration.

\(^a\) https://www.fda.gov/media/73072/download.

\(^b\) https://www.fda.gov/media/73072/download.

\(^c\) https://www.fda.gov/media/96528/download.

\(^d\) May not be resided in time for fresh donation.

- Psychoeducational evaluation and counseling by a qualified mental health professional is strongly recommended for all donors (see “Psychoeducational Counseling—Donors and Recipients”).
- The donor should undergo appropriate genetic evaluation, as reviewed in the genetic counseling section (see “Genetic Screening and Counseling”).

iv. Directed (nonanonymous/known) oocyte donation. Directed oocyte donors must undergo the same screening and testing as non-identified (anonymous) donors. Directed donors who test positive or demonstrate a risk of a relevant communicable disease are deemed “ineligible” for non-identified (anonymous) donation but are not prohibited from participating in directed donation according to current FDA rules, provided that both parties are aware of the donation’s theoretical infectious or genetic risk and have provided their consent to go ahead with the donation. Although the FDA does not inform the recipients of the test results other than their eligibility status, in the opinion of ASRM, the recipients must be informed and appropriately counseled with the donor’s consent before using the samples.

v. Quarantine of oocytes. Quarantine of oocytes is not required by FDA for non-identified (anonymous) or directed donation.

vi. Requirements of clinics providing oocyte donation services.
- If sharing of oocytes from an ART cycle is contemplated, informed consent must be obtained before the start of the cycle of retrieval. The conditions governing the sharing of oocytes should be specified in advance, be included in the informed consent, and comply with the existing ASRM Ethics Committee’s opinion documents (13).
- No owner, operator, laboratory director, trainee, or employee of a facility screening for or performing oocyte donation may serve as a donor in that practice.
- If an agency is used to recruit oocyte donors, no individual who has a financial interest in that agency may be used as an oocyte donor.

- Assurance that the oocyte donor has medical insurance or that the practice has a policy to cover donation-related medical expenses or complications.

c. Embryo Donation

In the current clinical practice of ART, more embryos than can be safely transferred at a time are often generated and may be cryopreserved for transfer later. Couples who become pregnant and do not desire another pregnancy or have other reasons for choosing not to use their embryos have the option of discarding these embryos or donating them to other individuals or for research (1). The purpose of this document is to present guidance for embryo donation. It should be noted that this guidance represents minimum standards for the screening, testing, and counseling of potential embryo donors and recipients. The US federal government has published the minimum requirements for embryo donation (14). Some states and other localities may have laws or regulations that pertain to embryo donation that may supersede this guidance.

i. Guidance for ART practices that offer embryo donation.
- The practice should be knowledgeable in the storage, thawing, and transfer of frozen embryos.
- The practice may charge potential recipients a professional fee for embryo thawing, embryo transfer procedure, cycle coordination and documentation, and infectious disease screening and testing of both recipients and donors. However, the selling of embryos per se is ethically unacceptable.
- Physicians and employees of an infertility practice should be excluded from participating in embryo donation as either donors or recipients within that practice.

ii. Donor embryo screening. The donor screening requirements recommended by FDA and additional recommendations by ASRM are summarized in Table 3.

iii. Donor embryo eligibility. Embryos derived from the gametes of a sexually intimate couple and created for use by that couple are exempted from the requirements for donor screening and testing before the creation of the embryos.
The following guidance applies to sexually intimate couples who decide to donate unused embryos that are a product of their own biological gametes:

a. Embryo donors should provide details of their medical and genetic history (see “Genetic Screening and Counseling”).

b. Gamete donors used to create embryos should be screened for relevant risk factors for HIV, other transmissible infections, and transmissible spongiform encephalopathy [15].

c. There is no method to completely ensure that infectious agents will not be transmitted, but the following guidance, combined with adequate information about the donor’s medical history and specific exclusion of individuals at a high risk of HIV and other transmissible infections, should dramatically reduce these risks. The practice should determine if the cost of such tests will be borne by the donor couple, the practice mediating the embryo donation, or the potential recipients (see “FDA Donor Eligibility Laboratory Testing”).

d. Often, the screening and testing of the biological source of the gametes used to create the embryos in sexually intimate partners is not performed, and the decision to donate embryos occurs subsequent to their creation. If the decision to donate is made >180 days after cryopreservation of the embryos, the donors may be screened and tested. In this instance, the documentation that accompanies the embryos must include the following label: “Advise recipient that screening and testing of the donors were not performed at the time of cryopreservation of the reproductive cells or tissue but have been performed subsequently.”

e. If the donors are not available or refuse to undergo the required screening and testing, the FDA guidance does not preclude the use of their embryos, provided that the documentation that accompanies the embryos includes the following labels: “NOT EVALUATED FOR INFECTIOUS SUBSTANCES” and “WARNING: Advise recipient of communicable disease risks.” However, ASRM recommends careful counseling regarding the risks of transfer of these embryos.

f. Embryos that are shipped to another facility must be accompanied by a summary of their records and must be appropriately labeled, in accordance with FDA guidance. The receiving facility should not accept embryos that are not accompanied by a summary of their records or those that are not appropriately labeled (4).

g. Embryo donors must sign an informed consent document indicating their permission to use their embryos for embryo donation. Issues to be addressed in the consent form include the following:
1. Relinquishing all rights of the donor(s) to the embryo(s) and any child or children that may result from the transfer of such embryo(s).
2. Recognition of inadvertent loss or damage to the embryo(s).
3. The right to practice refusal of transfer to an inappropriate recipient.
4. The time period for which donated embryos will be maintained in cryostorage and alternatives for their disposition thereafter.

5. Jurisdiction and process for medical/legal procedures and/or dispute resolution.

6. Possibility that the embryos will not be selected by potential recipients and that practices can then choose an alternative disposition, such as discarding the embryos.

h. Proper chain-of-custody procedures must be followed and documented for the handling of all test specimens and donated embryos.

i. Donors should receive no compensation for the embryos.

j. The decision to proceed with embryo donation is complex, and patients may benefit from psychological counseling (see “Psychoeducational Counseling—Donors and Recipients”).

iv. Situations in which the gamete source is a donor not an intimate partner. The eligibility of donors is determined by the gametes (donor oocyte or donor sperm) and not by the embryos that are donated. For embryos derived from gametes obtained from (a) non-identified (anonymous) donor(s), the donor(s) should have met all the FDA screening and testing requirements and should have been deemed eligible for non-identified (anonymous) donation, as previously described, for non-identified (anonymous) sperm and/or oocyte donation. The donor should also have consented to potential future embryo donation.

III. MANAGEMENT OF SPERM/OOCYTE DONORS

- Monitoring health status: The single most important method for reducing the risk of transmitting infectious agents is to carefully screen and test potential donors and develop an ongoing procedure for monitoring their health status.

- Payment to donors: Payment to donors varies from area to area but should not be such that monetary incentive is the primary motivation for gamete donation. However, the donor may be compensated for time and expenses. Please see the ethics committee’s opinion document titled “Interests, rights, and obligations in gamete donation: an ethics committee opinion” [16].

- Limitations to donor use: Institutions, clinics, and sperm banks should maintain sufficient records to allow a limit to be set for the number of pregnancies for which a given donor is responsible. It is difficult to provide a precise number of times that a given donor can be used because one must take into consideration the population base from which the donor is selected and the geographic area that may be served by a given donor. It has been suggested that in a population of 800,000, limiting a single donor to no more than 25 births would avoid any significant increased risk of inadvertent consanguineous conception [11]. This suggestion may require modification if the population using DI represents an isolated subgroup or if the specimens are distributed over a wide geographic area [16]. Oocyte donors should be limited to 6 cycles per donor. The basis for this recommendation is rooted in a concern over a cumulative risk of the donor after undergoing >6...
ovarian stimulation and oocyte retrieval procedures (11). When splitting donor embryo batches, the potential risk of siblings in a close geographic proximity should be considered. Additionally, donors should be informed about future potential request for follow-up testing or receipt of follow-up medical information that stems from a medical diagnosis in a donor-conceived child.

- **Consent:** It is essential for a donor to sign a consent form, which should include firm denial of having any recognized risk factors for STDs and genetic diseases. It has been recommended that the donor acknowledge in the consent form his/her responsibility to notify the donor program of any changes in health or risk factor status related to new diagnoses in the donor or his/her family members. The consent form should also consider addressing the donor’s consent or dissent with the use of resultant embryos for embryo donation.

- **Counseling about the process:** Donors should be counseled about the number and type of infectious disease tests that will be performed and should be informed about how that information will be used and shared with others.
  - Oocyte donors should be informed about all relevant aspects of the medical treatment, including medications, monitoring, and oocyte retrieval, and should be informed about potential risks, including ovarian hyperstimulation and cycle cancelation, and the risks of oocyte retrieval.
  - Oocyte donors should be counseled about the possibility of an unintended pregnancy and offered options for prevention.

- **Record-keeping:** The Food and Drug Administration requires that records pertaining to each donor (screening and test results) be maintained for at least 10 years; some states may be required to maintain record for longer. However, in the opinion of ASRM, a permanent record of each donor’s screening and test results should be maintained. As far as possible, clinical outcome should be recorded for each donation cycle. A mechanism to maintain such records should exist as a future medical resource for any offspring produced.

- **Protection of confidentiality:** Medical records detailing the donation should be maintained as stipulated by federal and local requirements.

**IV. RECIPIENTS AND THEIR PARTNERS—SCREENING AND TESTING**

**a. ASRM-Recommended Evaluation of Recipients**

i. **A routine assessment of health and reproductive history.** should be performed according to the general preconception screening standards that are applied to individuals anticipating pregnancy. The goal of preconception care is to reduce the risk of adverse health effects for the woman, fetus, and neonate by working with the woman to optimize health, address modifiable risk factors, and provide education (17). This should include (but is not limited to) review of medical, surgical, and psychiatric histories; review of current medications; evaluation of the risk of family and genetic histories; substance use assessment; evaluation of exposure to violence; assessment of immunization status, nutritional status, weight, physical activity, and possible teratogenic exposures.

ii. **A complete general physical examination.** should be performed, including pelvic examination. For embryo or oocyte recipients, formal assessment of the uterine cavity using saline infusion ultrasonography or another suitable procedure is recommended before treatment to assess for any significant uterine abnormality.

iii. **Donor gamete or embryo recipient laboratory testing.** Although there are no federal requirements for testing gamete or embryo recipients, the following tests are recommended to optimize perinatal care:

   a. Blood type, Rh factor, and antibody screen: Consideration should be given to blood type and Rh factor, particularly for Rh-negative recipients. If the use of donor gametes or embryo(s) creates a potential for Rh incompatibility, recipients should be informed of the obstetric implications of the condition.

   b. Assessment of vaccination status as per current guidance: Immunity against rubella and varicella should be documented before pregnancy. If nonimmune, the vaccine should be administered and pregnancy should be avoided for 4 weeks. Influenza and tetanus-diphtheria vaccination should be completed before pregnancy but can be administered during pregnancy (18).

   c. Infectious disease testing: Serologic test for syphilis, hepatitis B surface antigen, hepatitis C antibody, Neisseria gonorrhoeae, Chlamydia trachomatis, HIV, and cytomegalovirus (CMV) immunoglobulin G (IgG) antibody for women using donor sperm.

   i. Tests for human T-cell lymphotropic virus (HTLV) types I and II may also be performed at the discretion of a clinician in an appropriate clinical setting.

   ii. Positive test results for infectious disease warrant treatment and, if appropriate, referral to an infectious disease specialist. Positive test results should not preclude treatment assuming that informed decision-making and a comprehensive treatment plan are in place before pregnancy is attempted.

   d. Abnormalities detected based on history, physical examination, or laboratory evaluation may require more detailed evaluation and treatment. Additional guidance is available from ASRM regarding the provision of fertility treatment services to women at a high risk of pregnancy complications (19, 20).

**b. ASRM-Recommended Recipient Partner Screening**

Sexually intimate partners of individuals planning to receive oocyte, sperm, or embryos should be screened for infectious diseases. While not recommended by FDA, ASRM recommends that the partner be tested for infectious disease to
address any potential medical or legal issues that could arise should the partner seroconvert during or after treatment. Such screening of the partner is optional, particularly if the risk of infectious disease transmission is low, such as in the case of same-sex female partners planning donor sperm insemination.

Testing for STIs, similar to that recommended for the recipient partner, is encouraged. This includes serologic tests for HIV, syphilis, hepatitis B surface antigen, and hepatitis C antibody and nucleic acid amplification test for *Neisseria gonorrhoeae* and *Chlamydia trachomatis*. It is worth noting that there are no FDA-licensed, approved, or cleared tests for the screening of these organisms in an asymptomatic, low-prevalence population. Human T-cell lymphotropic virus types I and II and CMV immunoglobulin M (IgM) and IgG may also be obtained at the discretion of a clinician in an appropriate clinical setting.

**V. PSYCHOEDUCATIONAL COUNSELING—DONORS AND RECIPIENTS**

**a. ASRM-Recommended Psychoeducational Counseling—Donors**

A clinical evaluation by a qualified licensed mental health professional who has received training and education in third-party reproduction is strongly recommended for all donors considering gamete donation. The decision to proceed with gamete donation is complex, and the following recommendations are intended to provide general guidelines for addressing several moral, ethical, emotional, and social issues related to gamete donors, recipients, and donor-conceived persons:

i. The evaluation includes a clinical interview and standardized, empirically validated test that is designed for the assessment and/or screening of mental and behavioral disorders and should adhere to the established standards of professional and ethical practice.

ii. Mental health history should include the following:
- Family history
- Educational background
- Work history
- Financial stability
- Motivation to donate
- Current life stressors and coping skills
- Difficult or traumatic reproductive history
- Interpersonal relationships
- Sexual history
- Personal history of mental health issues, diagnoses, and substance use disorder and treatment
- Family history of psychiatric and personality disorders and substance use disorders
- Current or previous use of psychoactive medication
- Legal history
- History of abuse or neglect

iii. The evaluation should also assess for the donor’s understanding of the following:
- Potential emotional and social risks
- Evidence of coercion (financial or emotional)
- Information that will be disclosed to the donor or shared with others

iv. For donors who undergo additional cycles, a new full evaluation is strongly recommended if >24 months have elapsed since the previous evaluation.

v. Relative exclusion criteria for a gamete donor are as follows:
- Presence of significant psychopathology
- Positive family history of psychiatric disorders
- Current use of psychoactive medication
- Substance use disorders
- Two or more first-degree relatives with substance use disorders
- History of emotional, sexual, or physical abuse without professional treatment
- Excessive stress
- Relationship instability
- Inadequate cognitive functioning to support informed consent
- High-risk sexual practices
- Risks/concerns for the donor for future contact with donor-conceived offspring

vi. For directed donors and recipients, partners should be included in the clinical interview. The goal is to provide information and education about family-building, including discussion regarding the potential impact of donation on their relationships, contact with the donor, role expectations, and the children’s interests between and among each other.

vii. Candidates who are ineligible for donation should be offered a referral for any psychological or safety concerns.

**b. Psychoeducational Consultation: Gamete Donation Recipients (Oocytes, Sperm, and Embryos)**

The decision to proceed with oocyte, sperm, or embryo donation is complex, and intended parents benefit from counseling to aid with the decision. For these reasons, a psychoeducational consultation with a qualified licensed mental health professional who has training and education in third-party reproduction is strongly recommended.

A psychoeducational consultation addresses the implications of creating a family using gamete donation. Recipient(s) should be counseled about the potential emotional, moral, ethical, and social implications concerning building a family
using gamete donation. Different circumstances may require counseling that focuses on one or more of the following issues:

i. Disclosure  
ii. Implications of long-term impact on the family  
iii. Needs of donor-conceived persons  
iv. Grief and loss  
v. Limitations of donor screening  
vi. Desired qualities of the donor and its implications  
vii. Pregnancy, transition to parenthood, and parenting at an older age (if applicable)  
viii. Challenges of anonymity because of direct-to-consumer DNA testing, technological advances, social media, and implications for donor-conceived families  
ix. Future implications for the children of having persons who are linked through the same donor.  
x. Future implications of receiving new medical information about the donor or another donor-conceived sibling  
xi. Impact of treatment failure, coping with treatment termination, and developing alternative plans for the future  

Because the goal of this is psychoeducational, should information arise that indicates that there are concerns for the health, mental health, welfare, or safety of the recipient(s) or resulting children, a referral to an independent qualified professional should be made for an evaluation.

c. Psychoeducational Consultation: Gamete (Sperm and Oocyte) Donation with a Directed Donor  

In addition to the previous topics, a directed donation consultation should include the following:

i. In cases involving directed donors, separate consultation sessions for the donor(s) and recipient(s) as well as a joint session with the donor, donor’s partner, and recipient(s) are strongly recommended

ii. Expectations for communication and relationship roles between and among the donor, recipient, donor-conceived persons, partners, and other family members

iii. A donor may not be recommended for donation

iv. Exploration of donor and recipient preferences about the disposition of any remaining gametes or embryos

d. Psychoeducational Consultation: Embryo Donation with a Directed Donor  

Embryo donation requires special considerations for recipients and donors, and a psychoeducational consultation should include:

i. Separate consultation sessions, which are strongly recommended for the donor(s) and recipient(s), as well as a joint session with the donor, donor’s partner, and recipient(s) to discuss expectations, communication, and future relationships

ii. Discussion with the recipient(s) about future implications for their children having full genetic siblings in other families

iii. Exploration of contact and roles between and among families

iv. Impact of possible treatment failure

v. Donor and recipient(s) plan regarding disposition of any remaining embryos

vi. Challenges of anonymity because of direct-to-consumer DNA testing, technological advances, and social media and implications for donor-conceived families

VI. GENETIC SCREENING AND COUNSELING—DONORS AND RECIPIENTS  
a. Genetic Carrier Screening for Heritable Diseases  

The decision to proceed with gamete donation is complex, and the following recommendations are intended to provide general guidelines for genetic considerations.

i. Recommended non-identified (anonymous) donor carrier screening.

a. Screening for cystic fibrosis, spinal muscular atrophy, and thalassemia/hemoglobinopathy carrier status should be performed on all oocyte and sperm donors [21]

b. Routine carrier screening for fragile X syndrome carrier status may be considered for all oocyte donors regardless of family history. Screening for fragile X syndrome carrier status should be performed on all oocyte donors with a family history of fragile X-related disorders or intellectual disability suggestive of fragile X syndrome.

c. Additional expanded carrier screening may also be appropriate. Panethnic expanded carrier screening is recommended over ethnicity-based panels, given the limitations of self-reported ethnicity, increasing multinational populations, given that rare recessive conditions can occur in any ethnic group despite lower carrier frequencies. It is important to note that different panels may test for different conditions; ideally, oocyte and sperm sources should be screened for the same conditions. If carrier screening is performed using different panels in the same or different laboratories, ideally, a professional should review the results to evaluate and disclose the reproductive risk to help determine whether additional screening is warranted.

d. Embryo donors may not meet the preceding genetic carrier screening recommendations, particularly if the embryos were created using autologous oocytes and sperm. Updated genetic screening may be requested of embryo donors, if desired, but should not be considered a barrier to donating.

e. Recipients using a directed donor should be offered the preceding carrier screening options for their directed donor.

ii. Donor counseling.

a. Donors should provide informed consent, ideally through a written consent form, before carrier screening.

b. Informed consent should include the following details: a description of the test, types and number of conditions included, chance that the donor will be found to be a carrier, implications of being a carrier, possibility for recontact for additional samples or testing in the future, and